Mitsudomi Tetsuya

ミツドミテツヤ | Mitsudomi Tetsuya

Affiliation and department：
Homepage URL (1)： http://kaken.nii.ac.jp/d/r/70209807.ja.html

Research field (4)： Hematology and oncology , Respiratory surgery , Human pathology , General surgery, pediatric surgery

Research keywords (30)：肺癌 , 腺癌 , p53 , 予後因子 , 分子標的治療 , 獲得耐性 , EGFR , TTF-1 , 遺伝子変異 , 個別化医療 , p53遺伝子 , K-ras , 腫瘍抑制遺伝子 , 癌遺伝子 , 遺伝子増幅 , 上皮成長因子受容体(EGFR) , microsatellite polymorphism , LOH , EGFR変異肺癌 , HER2 , ELISA , PIK3CA , 喫煙 , 上皮成長因子受容体 , 神経内分泌マーカー , 免疫組織化学 , データベース , 9p , 感受性因子 , Peutz-Jeghers syndrome

Research theme for competitive and other funds (21)：

2022 - 2025 Targeted therapy for the patient with KRAS mutant lung cancer
2020 - 2023 Highly efficient establishment of lung cancer patient-derived organoids and its application for prediction of sensitivities to various treatments
2019 - 2022 Development of a new treatment strategy for HER2-alterated lung cancer
2016 - 2019 Molecular targeted therapy against adenocarcinoma of the lung harboring MET exon 14 skipping mutation
2011 - 2011 肺癌のキナーゼ阻害剤治療の新しい展開・獲得耐性の克服と新規標的の探索

2009 - 2011 Analysis of lung adenocarcinoma according to molecular biological classification

2008 - 2010 Molecular analysis of lung adenocarcinomas that do not have mutations in the EGFR pathway and development of therapeutic strategies against them

2007 - 2008 Inhibition of metastasis and tetraspanin expression by the human monoclonal antibody directed to CD151 and RNA interference

2006 - 2008 Tailor-made cancer diagnosis by systematically detecting alterations of miRNA and protein expressions

2006 - 2007 Clinical appliance to patients with lung cancer by human monoclonal antibody recognized Aminopeptidase N.

2006 - 2007 Analyses of EGFR and related molecules for individulaization of geftinib treatment for lung cancer

2004 - 2005 Molecular and Clinical database and Molecular Staging for Lung Cancer

2003 - 2005 Integrated system of the tailor-made cancer treatment based on the expression profiling and bioinformatic analyses

2002 - 2003 Clinical significance of comprehensive expression analysis of cancer-related protein in non-small cell lung cancer using tissue microarray technology

2000 - 2001 Suppression of metastasis due to regulation of Aminopeptidase-N

1998 - 1999 Cancer Gene Therapy with Adenovirally or Immunogene TM4SF

1998 - 1999 The analysis and a molecular staging protocol using reliable markers in predicting the prognosis of patients with lung cancer

1997 - 1999 Development of immunotherapy for lung cancer utilizing p53 specific cytotoxic T lymphocytes

1992 - 1994 Alterations in oncogenes and tumor suppressor genes on human lung cancer as a treament guideline

1991 - 1992 Comparative study on female lung cancer in Japan, USA, China

1989 - 1989 培養線維芽細胞を用いた発関遺伝子,温熱感受性及び熱ショック蛋白合成の関連の検討

Show all

Papers (629)：

Shigehiro Yagishita, Yasushi Goto, Makoto Nishio, Hiroaki Akamatsu, Hidetoshi Hayashi, Satoru Miura, Koji Tamada, Hiroshi Kagamu, Akinobu Hamada, Mayu Ohuchi, et al. Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL. JTO clinical and research reports. 2024. 5. 7. 100683-100683
Shota Fukuda, Kenichi Suda, Akira Hamada, Hana Oiki, Shuta Ohara, Masaoki Ito, Junichi Soh, Tetsuya Mitsudomi, Yasuhiro Tsutani. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study. Biomedicines. 2024. 12. 7
千葉眞人, 宗淳一, 老木華, 深見朋, 福田祥, 小原秀太, 濱田顕, 下治正樹, 武本智樹, 須田健一, et al. 低侵襲アプローチによる肺縮小手術最小の創で最小の肺切除,最新の取り組み. 気管支学. 2024. 46. 2. 132-132
Rie Shimizu, Kenichi Suda, Toshiki Takemoto, Shota Fukuda, Masato Chiba, Masaki Shimoji, Junichi Soh, Tetsuya Mitsudomi, Yasuhiro Tsutani. A case of late-onset bleeding from an intercostal artery pseudoaneurysm after hemostasis using soft coagulation. Surgical case reports. 2024. 10. 1. 49-49
Satoshi Ikeda, Masahiro Tsuboi, Kazuko Sakai, Toshihiro Misumi, Hiroaki Akamatsu, Hiroyasu Shoda, Noriaki Sakakura, Atsushi Nakamura, Yasuhisa Ohde, Hidetoshi Hayashi, et al. NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study. Molecular oncology. 2023

ｍore...

MISC (1,250)：

庄田浩康, 池田慧, 坪井正博, 坂井和子, 三角俊裕, 赤松弘朗, 棚橋雅幸, 丹保裕一, 齋藤春洋, 豊岡伸一, et al. 完全切除後II-III期のEGFR変異陽性非小細胞肺癌に対する第III相IMPACT試験における付随バイオマーカー研究. 肺癌. 2023. 63. 5. 499-499
濵田顕, 須田健一, 津谷康大, 光冨徹哉. EGFR陽性肺癌におけるEGFR-TKIを用いた術後補助療法-Adjuvant therapy using EGFR-TKI in resected EGFR-mutated NSCLC-特集肺癌診療ガイドライン2022年版を読み解く : 薬物治療を中心に ; 周術期治療. 呼吸器内科 = Respiratory medicine / 呼吸器内科編集委員会編. 2023. 44. 4. 387-391
富沢健二, 老木華, 西野将矢, 佐藤克明, 光冨徹哉. 原発性肺癌におけるGeriatric Nutritional Risk Indexの臨床病理学的意義. 日本外科学会定期学術集会抄録集. 2023. 123回. DP-3
須田健一, 小原秀太, 濱田顕, 千葉眞人, 伊藤正興, 下治正樹, 武本智樹, 宗淳一, 光冨徹哉, 津谷康大. 肺がん周術期がん免疫治療の現状とバイオマーカー. 日本気管食道科学会総会ならびに学術講演会プログラム・予稿集. 2023. 74th
須田健一, 小原秀太, 宗淳一, 津谷康大, 光冨徹哉. Minimal Residual Disease. 日本癌治療学会学術集会(Web). 2023. 61st

ｍore...

Professional career (1)：

医学博士 (九州大学)

Work history (3)：

2022/04 - 現在 Kindai University Hospital Global Research Alliance Center Specially-appointed Professor
2012/05 - 2022/03 Kindai University Faculty of Medicine
1995/10 - 2012/04 愛知県がんセンター病院呼吸器外科部/研究所分子腫瘍学部部長/研究員

Association Membership(s) (14)：

European Society for Medical Oncology , American Association of Clinical Oncology , American Association for Cancer Research , International Association for the Study of Lung Cancer , 日本内視鏡外科学会 , 日本癌治療学会 , 日本呼吸器内視鏡学会 , 日本外科学会 , 日本呼吸器学会 , 日本臨床腫瘍学会 , 日本癌学会 , 日本肺癌学会 , 日本呼吸器外科学会 , 日本胸部外科学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page